Hepatitis Clinical Trials

Showing 901-920 of 1,819 trials

Conquering Hepatitis C Via Micro-Elimination in Southwest Virginia

NCT03876470

The objective of this protocol is to conduct a comprehensive quantitative and qualitative assessment of the impact of our innovative collaborative telehealth HCV care model on patient treatment experiences and quality of life.

Hepatitis C

University of Virginia300 participantsStarted May 2019

COMPLETEDPhase 1

A Study to Assess DV-601 in Subjects With Chronic Hepatitis B

NCT01023230

The purpose of this study is to determine if DV-601, an investigational, therapeutic vaccine will be well-tolerated and induce hepatitis B virus (HBV)-specific virological and immunological responses in chronic hepatitis B (CHB) patients.

Hepatitis B, Chronic

Dynavax Technologies Corporation14 participantsStarted Sep 2009

Bydgoszcz, Poland • Szczecin, Poland • Warsaw, Poland +1 more locations

COMPLETEDPhase 1

Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection

NCT00823862

To determine safety, tolerability, and preliminary efficacy of escalating doses of SD-101 alone and SD-101 plus ribavirin in subjects with chronic hepatitis C and no prior therapy.

Chronic Hepatitis C

Dynavax Technologies Corporation34 participantsStarted Oct 2008

Bydgoszcz, Poland • Lublin, Poland • Warsaw, Poland +2 more locations

Conquering Hepatitis C Via Micro-Elimination in Southwest Virginia

A Study to Assess DV-601 in Subjects With Chronic Hepatitis B

Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection

Related Searches

Biologic Basis of Liver Cancer From Chronic Hepatitis B

Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016)

Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study

Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada

Hepatocyte-specific Versus Extracellular Contrast Agents for Liver MRI: Prospective, Intra-individual Comparison of Diagnostic Performance for Hepatocellular Carcinoma

A Safety and Efficacy Study of a Single or Double Dose of HEPLISAV™ Hepatitis B Vaccine in Adults With End-Stage Renal Disease

A Study of the Immune Response to Heplisav in Healthy Older Adults

The Effect of Viral Load on Intrahepatic Recurrence in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC)

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy

Feasibility of VIIT in Adults With NASH

Outcomes in Liver Disease Patient With and Without HIV Co-infection-Sub Study 2: HCV Treatment: Health Related Quality

Bioequivalence Study of Entecavir Tablets and Baraclude® Under Fasting Condition in Chinese Healthy Volunteers

Evaluation of Antiviral Indications on Chronic HBV Infection With Different Transaminase Levels

Study of Combination Treatment With IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients

Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients

Efficacy of GZR/EBR in Early Chronic Hepatitis C in HIV/HCV Co-infected Patients